CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
SRIGX
Price
$13.90
Change
+$0.13 (+0.94%)
Updated
Jun 2 closing price
Net Assets
22M
Interact to see
Advertisement

CWIAX vs SRIGX

Header iconCWIAX vs SRIGX Comparison
Open Charts CWIAX vs SRIGXBanner chart's image
CWIAX vs SRIGX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. SRIGX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and SRIGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. SRIGX (22M). CWIAX (1.33) and SRIGX (1.29) have matching dividends . CWIAX was incepted earlier than SRIGX: CWIAX (24 years) vs SRIGX (19 years). SRIGX (2.24) is less costly to investors than CWIAX (0.75). CWIAX is a more actively managed with annual turnover of: 44.00 vs. SRIGX (20.00). CWIAX has a lower initial minimum investment than SRIGX: CWIAX (250) vs SRIGX (1000). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. SRIGX (6.43). CWIAX return over 5 years is better than : 38.19 vs. SRIGX (-9.21).
CWIAXSRIGXCWIAX / SRIGX
Total Expense Ratio0.750.9083%
Annual Report Gross Expense Ratio0.752.2433%
Fund Existence24 years19 years-
Gain YTD15.6524.318362%
Front Load4%N/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets152B22M690,909%
Annual Yield % from dividends1.331.29103%
Returns for 1 year22.446.43349%
Returns for 3 years54.6517.80307%
Returns for 5 years38.19-9.21-414%
Returns for 10 years122.630.9313,250%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C